Gunderson Dettmer represented client Section 32 on the deal while Wilson Sonsini advised BigHat Biosciences. Section 32, a venture capital fund that invests in frontiers of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Matchwell on the deal. Medical Solutions, one of the nation’s largest providers of total workforce solutions serving the healthcare industry,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Trutino Biosciences on the deal. Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced the signing of an option to acquire...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, a leader in the development of automated solutions for on-demand synthesis of genes...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised ABL on the deal. ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Akili on the deal. PureTech Health plc (PureTech), a clinical-stage biotherapeutics company, announced that its Founded Entity, Akili Interactive (Akili),...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Simplify Medical on the deal. NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally...
You must be a Standard 1 Year member to access this content.
